Moderna (MRNA) has recently made numerous strides in its mRNA technology. They have announced a significant achievement; the delivery of the first Made-in-Canada mRNA vaccines to provinces and territories. The company also had their stock price target set to $32.00 by Morgan Stanley. Comparisons between Moderna's mRNA-1083 vaccines and Pfizer's dual-target mRNA vaccines for flu and COVID-19 have been made, with Moderna revealing strong immune responses in patients from their updated next-generation COVID shots. The COVID shot has also resulted in less severe illness and fewer hospitalizations, according to a US study. Notably, Moderna's flu vaccine trial has demonstrated promising efficacy results. Despite facing some obstacles, such as the RFK Jr.'s attack on mRNA vaccines, the company continues to progress in their research and investments. However, they have recently faced accusations from RFK Jr., which have resulted in the cancellation of $500m in mRNA vaccine development in the US, adding a layer of complexity to Moderna's ongoing efforts.
Moderna MRNA News Analytics from Sat, 11 Jan 2025 08:00:00 GMT to Sat, 11 Oct 2025 18:03:37 GMT - Rating 4 - Innovation 6 - Information 8 - Rumor -3
